Leveraging a Clinical Phase Ib Proof‐of‐Concept Study for the GPR40 Agonist MK‐8666 in Patients With Type 2 Diabetes for Model‐Informed Phase II Dose Selection

GPR40 mediates free fatty acid–induced insulin secretion in beta cells. We investigated the safety, pharmacokinetics, and glucose response of MK‐8666, a partial GPR40 agonist, after once‐daily multiple dosing in type 2 diabetes patients. This double‐blind, multisite, parallel‐group study randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Krug, AW, Vaddady, P, Railkar, RA, Musser, BJ, Cote, J, Ederveen, AGH, Krefetz, DG, DeNoia, E, Free, AL, Morrow, L, Chakravarthy, MV, Kauh, E, Tatosian, DA, Kothare, PA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593169/
https://www.ncbi.nlm.nih.gov/pubmed/28727908
http://dx.doi.org/10.1111/cts.12479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593169/
https://www.ncbi.nlm.nih.gov/pubmed/28727908
http://dx.doi.org/10.1111/cts.12479

Ejemplares similares